Skip to content [s] Site map [3] Home [1]
Graphic text
Button

A Talented and Dedicated Research Team

At the heart of CHRISTUS Stehlin Foundation are dedicated scientists, administrative staff, and a hardworking board. The vision began with founder Dr. John S. Stehlin, Jr. and continues with President Robert F. (Bobby) Anderson, who has served as the Foundation’s Executive Director since 1991. All Stehlin staff members are dedicated to our mission, as evidenced by an average tenure of 16 years.

Noted Achievements

Stehlin physicians and scientists have shared their research discoveries and innovative treatment methods through more than 500 articles published in top national and international science and medical journals.

Stehlin scientists and staff are also active in community services and education. Researchers and other professionals speak on a variety of cancer related topics at local, national, and international meetings, private groups and functions, and radio and television talk shows throughout the year.

The Foundation has collaborated with a number of internationally renowned physicians and scientists at many of the world’s most prestigious public and private research facilities. Institutional collaborations include:

 


Our Team

Compared with other anticancer drugs at similar stages of development, camptothecins have demonstrated a much higher anticancer activity. Camptothecins can be envisioned as the ultimate anticancer drug when fully developed.”

National Academy of Science, 1995

News

In Mice, Cancer Drug Shows Effect on Alzheimer's Symptoms

The cancer drug bexarotene quickly eliminates Alzheimer's disease-associated amyloid beta from the brain and reverses memory problems in mice, a new study finds. The results suggest that bexarotene could help the 5.4 million Americans with Alzheimer's disease.

Genetic Breakthrough for Brain Cancer in Children

An international research team has made a breakthrough that could change the way pediatric cancers are treated in the future. The researchers identified two genetic mutations responsible for up to 40 per cent of glioblastomas in children.

Skin Cancer Drug Approved

Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer.

All News


Share this Page

Stay Connected

Button Button Button Button

Get Hope!

Sign up for our newsletter and updates.

CHRISTUS Stehlin Foundation for Cancer Research

10301 Stella Link Road, Suite A
Houston, Texas 77025-5447
713.659.1336


Affiliates and Resources

Logo Logo Logo Logo Logo


Button